vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and SCANSOURCE, INC. (SCSC). Click either name above to swap in a different company.
SCANSOURCE, INC. is the larger business by last-quarter revenue ($766.5M vs $708.5M, roughly 1.1× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 2.2%, a 16.9% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 2.5%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $28.9M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 0.9%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
ScanSource, Inc. is a leading global specialty technology distributor offering a broad portfolio of solutions including point-of-sale systems, barcode scanning tools, cybersecurity products, cloud services and communication solutions. It primarily serves value-added resellers, managed service providers and enterprise clients across North America, Latin America and Europe, covering retail, healthcare, industrial and public sector core segments.
MEDP vs SCSC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $766.5M |
| Net Profit | $135.1M | $16.5M |
| Gross Margin | — | 13.4% |
| Operating Margin | 21.6% | 2.3% |
| Net Margin | 19.1% | 2.2% |
| Revenue YoY | 32.0% | 2.5% |
| Net Profit YoY | 15.5% | -3.3% |
| EPS (diluted) | $4.65 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $766.5M | ||
| Q3 25 | $659.9M | $739.6M | ||
| Q2 25 | $603.3M | $812.9M | ||
| Q1 25 | $558.6M | $704.8M | ||
| Q4 24 | $536.6M | $747.5M | ||
| Q3 24 | $533.3M | $775.6M | ||
| Q2 24 | $528.1M | $746.1M | ||
| Q1 24 | $511.0M | $752.6M |
| Q4 25 | $135.1M | $16.5M | ||
| Q3 25 | $111.1M | $19.9M | ||
| Q2 25 | $90.3M | $20.1M | ||
| Q1 25 | $114.6M | $17.4M | ||
| Q4 24 | $117.0M | $17.1M | ||
| Q3 24 | $96.4M | $17.0M | ||
| Q2 24 | $88.4M | $16.1M | ||
| Q1 24 | $102.6M | $12.8M |
| Q4 25 | — | 13.4% | ||
| Q3 25 | — | 14.5% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 14.2% | ||
| Q4 24 | — | 13.6% | ||
| Q3 24 | — | 13.1% | ||
| Q2 24 | — | 13.0% | ||
| Q1 24 | — | 12.6% |
| Q4 25 | 21.6% | 2.3% | ||
| Q3 25 | 21.5% | 3.5% | ||
| Q2 25 | 20.9% | 3.3% | ||
| Q1 25 | 20.3% | 3.2% | ||
| Q4 24 | 23.4% | 2.5% | ||
| Q3 24 | 21.1% | 2.3% | ||
| Q2 24 | 19.9% | 2.9% | ||
| Q1 24 | 20.4% | 2.3% |
| Q4 25 | 19.1% | 2.2% | ||
| Q3 25 | 16.8% | 2.7% | ||
| Q2 25 | 15.0% | 2.5% | ||
| Q1 25 | 20.5% | 2.5% | ||
| Q4 24 | 21.8% | 2.3% | ||
| Q3 24 | 18.1% | 2.2% | ||
| Q2 24 | 16.7% | 2.2% | ||
| Q1 24 | 20.1% | 1.7% |
| Q4 25 | $4.65 | $0.75 | ||
| Q3 25 | $3.86 | $0.89 | ||
| Q2 25 | $3.10 | $0.87 | ||
| Q1 25 | $3.67 | $0.74 | ||
| Q4 24 | $3.67 | $0.70 | ||
| Q3 24 | $3.01 | $0.69 | ||
| Q2 24 | $2.75 | $0.66 | ||
| Q1 24 | $3.20 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $83.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $459.1M | $910.9M |
| Total Assets | $2.0B | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $83.5M | ||
| Q3 25 | $285.4M | $124.9M | ||
| Q2 25 | $46.3M | $126.2M | ||
| Q1 25 | $441.4M | $146.3M | ||
| Q4 24 | $669.4M | $110.5M | ||
| Q3 24 | $656.9M | $145.0M | ||
| Q2 24 | $510.9M | $185.5M | ||
| Q1 24 | $407.0M | $159.1M |
| Q4 25 | $459.1M | $910.9M | ||
| Q3 25 | $293.6M | $914.0M | ||
| Q2 25 | $172.4M | $906.4M | ||
| Q1 25 | $593.6M | $901.7M | ||
| Q4 24 | $825.5M | $900.7M | ||
| Q3 24 | $881.4M | $920.9M | ||
| Q2 24 | $763.6M | $924.3M | ||
| Q1 24 | $671.5M | $944.1M |
| Q4 25 | $2.0B | $1.7B | ||
| Q3 25 | $1.8B | $1.7B | ||
| Q2 25 | $1.6B | $1.8B | ||
| Q1 25 | $1.9B | $1.7B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.1B | $1.8B | ||
| Q2 24 | $1.9B | $1.8B | ||
| Q1 24 | $1.8B | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $30.8M |
| Free Cash FlowOCF − Capex | $188.1M | $28.9M |
| FCF MarginFCF / Revenue | 26.6% | 3.8% |
| Capex IntensityCapex / Revenue | 0.6% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.43× | 1.87× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $30.8M | ||
| Q3 25 | $246.2M | $23.2M | ||
| Q2 25 | $148.5M | — | ||
| Q1 25 | $125.8M | $66.1M | ||
| Q4 24 | $190.7M | $-6.2M | ||
| Q3 24 | $149.1M | $44.8M | ||
| Q2 24 | $116.4M | — | ||
| Q1 24 | $152.7M | $160.2M |
| Q4 25 | $188.1M | $28.9M | ||
| Q3 25 | $235.5M | $20.8M | ||
| Q2 25 | $142.4M | — | ||
| Q1 25 | $115.8M | $64.6M | ||
| Q4 24 | $183.0M | $-8.2M | ||
| Q3 24 | $138.5M | $42.5M | ||
| Q2 24 | $103.5M | — | ||
| Q1 24 | $147.2M | $157.7M |
| Q4 25 | 26.6% | 3.8% | ||
| Q3 25 | 35.7% | 2.8% | ||
| Q2 25 | 23.6% | — | ||
| Q1 25 | 20.7% | 9.2% | ||
| Q4 24 | 34.1% | -1.1% | ||
| Q3 24 | 26.0% | 5.5% | ||
| Q2 24 | 19.6% | — | ||
| Q1 24 | 28.8% | 21.0% |
| Q4 25 | 0.6% | 0.3% | ||
| Q3 25 | 1.6% | 0.3% | ||
| Q2 25 | 1.0% | 0.3% | ||
| Q1 25 | 1.8% | 0.2% | ||
| Q4 24 | 1.4% | 0.3% | ||
| Q3 24 | 2.0% | 0.3% | ||
| Q2 24 | 2.4% | 0.2% | ||
| Q1 24 | 1.1% | 0.3% |
| Q4 25 | 1.43× | 1.87× | ||
| Q3 25 | 2.22× | 1.17× | ||
| Q2 25 | 1.65× | — | ||
| Q1 25 | 1.10× | 3.79× | ||
| Q4 24 | 1.63× | -0.36× | ||
| Q3 24 | 1.55× | 2.64× | ||
| Q2 24 | 1.32× | — | ||
| Q1 24 | 1.49× | 12.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
